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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYWe present a non-invasive method to characterize the function of pluripotent stem-cell-derived cardiomyocytes based on video micro-
scopy and image analysis. The platform, called Pulse, generates automatedmeasurements of beating frequency, beat duration, amplitude,
and beat-to-beat variation based on motion analysis of phase-contrast images captured at a fast frame rate. Using Pulse, we demonstrate
recapitulation of drug effects in stem-cell-derived cardiomyocytes without the use of exogenous labels and show that our platform can be
used for high-throughput cardiotoxicity drug screening and studying physiologically relevant phenotypes.INTRODUCTION
Recent advances in stem cell technologies have enabled
routine analysis of patient-derived cardiomyocytes, open-
ing up new opportunities for drug testing and personalized
health care. Numerous studies have demonstrated that
induced pluripotent stem-cell-derived cardiomyocytes
(iPS-CMs) display physiologically relevant characteristics
and patient-derived iPS-CMs recapitulate aspects of patient
cardiac pathology/phenotype in vitro (Harris et al., 2013;
Navarrete et al., 2013; Sun et al., 2012). iPS-CMs can be
used for preclinical testing of new drugs that may cause
drug-induced arrhythmia or QT prolongation and cardio-
toxicity, as well as for post-market safety testing or re-
purposing of existing Food and Drug Administration-
approved drugs (Guo et al., 2011; Liang et al., 2013; Sirenko
et al., 2013; Himmel, 2013). Improved cell-culturing tech-
nologies now allow for the production of well-character-
ized cardiomyocytes at scale, hence providing a reliable
source for routine screening applications. Therefore, accu-
rate and reliable characterization of these cells, and their
response to different chemical compounds plays a critical
role in their successful utilization in drug development
and safety testing.
An ideal platform for characterizing iPS-CMs would
ensure reproducibility, require small samples, provide a
reliable and comprehensive quantitative profile of cell
function, and be cost effective when run at large scales. La-
bel-free video microscopy has already been recognized as a
well-suited platform (Makino et al., 1999; Hossain et al.,
2010). For example, Ting et al. (2014) created a video-man-
agement platform that determines whether a specific re-
gion is beating; it segments and counts the beatingStempattern/signal of differentiated cardiomycytes with a
user-specified threshold on the average change in signal
intensity. Also, Ahola et al. (2014) captured the beating ac-
tivity of single cardiomyocytes by analyzing the motion
vector field of individual cells manually segmented by the
user. Similarly, researchers estimated beating profiles of car-
diomyocytes with a block-matching optical flow approach
(Huebsch et al., 2014). While this approach yields vector
fields of cellular motion for beating monolayer and sin-
gle-cell iPSC-CMs, it is computationally expensive and
may require manual tuning of the expectedmotion param-
eters and signal thresholds for each video. These efforts
show the promise of video microscopy and analysis;
however, we need an integrated and fully automated solu-
tion to characterize iPS-CMs at larger scales. This solution
must avoid manually tuning software parameters for each
video and also handle a broad range of cell-culture condi-
tions, such as varied cell densities and drug treatments.
Finally, to facilitate real-time monitoring at relatively low
cost, the algorithms used to identify motion must be rapid
and suitable for computational implementation without
the need for parallel computing.
In current practice, patch-clamp assays are the standard
reference for high-precision electrical measurements of
iPS-CMs (Peng et al., 2010). However, patch-clamp analysis
requiresmanual operation by a trained electrophysiologist.
Such assays are inherently low-throughput and will not
scale to meet the demands of large-scale drug testing. iPS-
CMs can also be characterized using electrical potentials
captured by a micro-electrode array (MEA) (Harris et al.,
2013). With an MEA system, the local potential in a region
consisting of electrically active cells is measured as a
function of time in order to generate a beating signal thatCell Reports j Vol. 4 j 621–631 j April 14, 2015 j ª2015 The Authors 621
contains information such as frequency, irregularity, and
QT interval. Such systems typically require high cell den-
sity in specialized plates and rely on direct contact between
cells and electrodes. Other methods, such as fluorescence
imaging of the calcium signals (Paredes et al., 2008), can
be useful, but are prone to phototoxicity aswell as potential
interactions between calcium indicators and the chemical
compounds being studied (Muschol et al., 1999).
In this paper, we present an all-in-one platform, Pulse,
which uses video microscopy and image-analysis algo-
rithms (Maddah and Loewke, 2014) to automatically cap-
ture and quantify the beating patterns of cardiomyocytes.
Our technique generates a beating signal that corresponds
to the biomechanical contraction and relaxation of iPS-
CMs, based on motion analysis of phase-contrast images
captured at up to 50 frames per second. From the beating
signal, various quantitative measurements such as beating
frequency, irregularity, and duration of a single contraction
are calculated.We designed a set of experiments to validate
and test the Pulse platform, performed successfully across
800 different videos, and used a diverse set of compounds
to investigate the extent to which Pulse can capture dose-
dependent responses of different drugs. Pulse is a fully
automated biomechanical contractile analyzer designed
to be compatible with common cell-culture practices (us-
ing standard multi-well plates) and completely non-inva-
sive to cells, making it ideal for large-scale cardiovascular
drug development and cardiotoxicity testing. It is worth
mentioning, however, that Pulse is not meant to replace
electrophysiology or other methods such as MEA or Ca2+
imaging altogether, but to supplement them. We envision
applications of Pulse as a primary screening tool that can be
used to efficiently and cost-effectively scan large numbers
of compounds for cardiotoxicity. Such studies could then
be followed up inmore detail with fewer andmore-targeted
patch-clamp assays.RESULTS
Video Motion Analysis
The Pulse video analysis software extracts and quantifies
beating signals from the video of cardiomyocytes. Our
method enables automated extraction of quantitative pa-
rameters that are of interest in clinical studies from cultures
with different cell densities and with either regular or irreg-
ular beating patterns. Specifically, it captures and quantifies
the biomechanical beating of cardiomyocytes by perform-
ing motion analysis on the image sequence to capture
changes in the image intensity due to cardiomyocyte
contraction and relaxation. The design of our algorithm
is guided by the fact that it should be possible to work on
different tissue types without the need for any parameter622 Stem Cell Reports j Vol. 4 j 621–631 j April 14, 2015 j ª2015 The Authotuning. This is whywe avoid the use of specific cell segmen-
tation algorithms and apply a more data-driven approach.
Figures 1A–1D diagrams the steps of the Pulse algorithm,
which includes (1) block-wise segmentation of the image
sequence, (2) extraction of the beating signal for each
block, (3) quantification of the beating signals, (4) outlier
rejection, and (5) clustering of the beating signals into a
set of unique signals, each representing a region of the
culture where cardiomyocytes beat in synchrony.
Extraction of Beating Signals
The algorithm first segments each image in the video
sequence into 30 non-overlapping blocks. Background
blocks, i.e., those that do not contain any cells, are
removed from further processing. Then a beating signal is
extracted for each block as follows. For every image and
each candidate beating block, a one-dimensional vector
of pixel intensities is constructed. Starting from the second
image in the sequence, the correlation coefficient of inten-
sity vectors of the image and its preceding image in the
sequence is computed. Figure 1E shows an example of a
beating signal extracted for one of the blocks. This relative
correlation signal typically exhibits three states: a resting
state, where the correlation between successive images is
high, a contraction state, and a relaxation state. Although
the beating pattern and frequency can be measured from
this signal, automatic identification of beating intervals is
challenging due to the presence of double peaks and the
lack of prior knowledge on their relative magnitude or dis-
tances. To obtain a single-peak signal, the algorithm first
estimates a reference image by taking the median of
resting-state images. An absolute correlation signal is then
generated by computing the correlation coefficient of the
intensity vector of the reference image with those of all
images in the sequence. Figure 1F shows an example of
the resulting signal.
Quantification of the Beating Signal
To capture irregularity and dynamics of beating profile
over time, we perform the analysis in the time domain
as opposed to frequency domain. The algorithm first iden-
tifies the peaks of the absolute correlation signal. A vector
of estimated beating intervals is constructed by calculating
the duration between successive peaks. We define the
effective beating rate based on the median of the vector
and define the irregularity of beating pattern based on
the interquartile range (IQR) of the vector. We define the
beat duration at 75% (meaning the duration is measured
at 25% of the peak magnitude in the absolute correlation
signal) and take the average duration over all beats.
Finally, peak height, which is a unit-less quantity, is a mea-
sure of contractility; stronger contraction results in larger
values for the peak height. Figure 1F schematically shows
how these measurements are performed on the beating
signal.rs
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Figure 1. Processing Steps of Pulse Video Analysis
(A) Block-wise segmentation of the image sequence; background blocks are excluded from further processing.
(B) A motion signal is estimated for each block, which can include noisy signals from moving debris.
(C) Signal processing is performed on each signal to identify peaks and model the shape of the beats, and to measure parameters such as
frequency and duration. If the beats in a signal are not similar, the signal is identified as outlier and is rejected.
(D) Beating signals with similar pattern are automatically clustered together.
(E) A relative correlation signal is estimated per block.
(F) From the relative correlation signal, the resting state is identified and is used a reference to measure the absolute correlation signal,
from which the quantitative parameters are automatically measured.Outlier Rejection
Once the absolute correlation signal is quantified, we
perform outlier rejection. Outliers can consist of noisy sig-
nals that occur due to moving debris or bubbles in the me-
dia. To keep the arrhythmia signals but reject the outliers,
we make the assumption that the beats in a signal should
have similar shapes. A Gaussian mixture model is fitted to
each beating signal, and the fitting error serves as a metric
to detect and reject signals that do not represent beating
of cardiomyocytes. Finally, the algorithm merges the valid
blocks that have similar beating patterns (Maddah and
Loewke, 2014), providing the user with a distinct set of sig-
nals per data set. To demonstrate the versatility of the algo-
rithm, Figure 2 shows a set of examples for different plating
densities and successful extraction of the beating signal.
Figures 2A and 2B are examples of monolayer and tissue-
like cultures respectively, where the beating blocks have
been identified successfully and clustered together as the
cells beat in synchrony. Figure 2C shows an example of sin-Stemgle-cell plating density where cells have not formed a syn-
cytium and thus beat asynchronously. In this scenario, the
algorithm processes each block, excludes the non-beating
blocks, and clusters the blocks with similar beating profile
together, assigning a distinct label to each cluster. In this
example, there are five beating signals corresponding to
the five regions marked in the upper picture of Figure 2C.
Clustered regions correspond to regions that do not beat
in synchrony.
Comparison of Motion Analysis with Patch Clamp
We designed a series of experiments to validate the Pulse
platform and demonstrate its ability to detect and measure
drug-induced changes to cardiomyocyte function. In a
first experiment, we compared the results of Pulse’s mo-
tion analysis to data collected by simultaneous manual
patch clamp (ChanTest Corporation; see experiment pro-
tocol in the Supplemental Experimental Procedures).
Phase-contrast imaging and patch-clamp recordings wereCell Reports j Vol. 4 j 621–631 j April 14, 2015 j ª2015 The Authors 623
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Figure 2. Successful Estimation of Beating Signals on Cardiomyocytes Cultured in Different Conditions
Example of cardiomyocytes with (A) monolayer (cells from Cellular Dynamics), (B) cardio-sphere (cells from Gladstone Institute), (C)
single cell (cells from Axiogenesis), corresponding to Movies S1, S2, and S3. In (C), there are five distinct beating signals corresponding to
the five regions marked in the upper picture. Clustered regions correspond to regions that do not beat in synchrony.performed simultaneously on iPSC-derived cardiomyo-
cytes (Cor.4U cell line by Axiogenesis). Figure 3 shows
the overlay of the signals measured by these two ap-
proaches on three independent cardiomyocyte samples.
As observed in the figure, the Pulse beating profiles pre-
cisely match the corresponding patch-clamp signals in
terms of beating patterns and beat duration. These results
confirm that the Pulse system is adequately sampling the
beating motion and is generating a reliable output. The
manual patch-clamp data were collected while simulta-
neously capturing a video sequence with a known sam-
pling rate. However, we were not able to record absolute
time stamps for both data sets, so the resulting traces
were manually aligned.
Comparison of Motion Analysis with Calcium
Transients
To compare how calcium transient signals compared to the
motion tracings generated by Pulse, we performed two sets
of experiments by either modulating calcium transient du-
rations (using quinidine) or inhibiting contraction (using
blebbistatin). The biomechanical motion of GCaMP cardi-
omyocytes (see Figure S1 for a description of genomic
modification, cell line derivation, and differentiation) was
captured on Pulse, followed by fluorescence video imaging
using Keyence BZ-9000 to measure GCaMP fluorescent
activity. Video imaging on both microscope systems was
repeated after the addition of compound and again after
compoundwashout. Two compoundswere used: blebbista-
tin, which inhibits contraction by blocking myosin II
(Abassi et al., 2012), while leaving calcium signaling unaf-
fected, and quinidine, a Na+ channel blocker, which has624 Stem Cell Reports j Vol. 4 j 621–631 j April 14, 2015 j ª2015 The Authobeen shown to increase action potential duration in hu-
man cardiomyocytes (Navarrete et al., 2013; Peng et al.,
2010).
Figure 4A shows the beating signal extracted by Pulse
30 min after addition of different concentrations of bleb-
bistatin. As the concentration of blebbistatin is increased,
the relative amplitude of the beating signal decreases,
serving as a functional readout for the expected reduction
in contractility. Figure 4B shows a comparison of the ampli-
tude of the beating signal before blebbistatin is added,
30min after compound application, and after a subsequent
media change. Note that the biomechanical beating of the
cardiomyocytes is restored back to normal levels after bleb-
bistatin is washed away. For a concentration of 1 mM or
above, no biomechanical beating is observed. In contrast,
fluorescence imaging of GCaMP continues to generate a
calcium transient signal even at 5 mM, as seen in Figure 5C.
These data demonstrate that Pulse is able to capture and
quantify the effect of a myosin II blocker in inhibiting
the biomechanical contraction of the cardiomyocytes, an
effect that MEA or Ca+2 imaging systems do not capture
(Abassi et al., 2012).
In a second experiment, we applied 3 mM quinidine to
GCaMP cardiomyocytes and performed video imaging
30 min after addition of the drug. Using Pulse, we detect
a 30% increase in the 75% duration of beat duration and
a 40% prolongation of the 75% duration as measured by
calcium imaging after drug addition. Figure 4D shows
that Pulse and Ca2+ imaging detect a comparable increase
in the 75% duration, indicating that a prolonged calcium




Figure 3. Overlay of Beating Signals Derived from Pulse and Patch Clamp
Patch-clamping data and video were collected concurrently. Motion-analysis-derived and electrophysiologically generated traces for three
independent cell cultures (A–C) with varying frequency and irregularity are overlaid, showing similar results.Pulse Captures Expected Effects of Commonly Used
Drugs on iPS-Derived Cardiomyocytes
We performed a set of experiments with a diverse panel of
compounds to demonstrate the strength and sensitivity of
Pulse in capturing dose-dependent responses to different
drugs. In this work, we show the results of eight commonly
used drugs with well-known effects on the beating pattern
of cardiomyocytes. Table 1 and Figure 5 show a summary of
the results. Aspirin was chosen as the negative control,
while the other seven drugs have known effects in chang-
ing the beat rate, inducing arrhythmias, or changing the
action potential duration.
All drugs used for this study were purchased from Sigma-
Aldrich, diluted in DMSO, subsequently frozen, and serially
diluted in pre-equilibratedmedia immediately prior to each
experiment. Each compoundwas tested at three concentra-
tions, in replicates of six wells with four recordings from
each well. For drug testing experiments, cryo-reserved
GCaMP cells were thawed and plated in 24-well plates and
allowed 5 days for recovery. Fresh pre-warmed and equili-
brated (37C; 5% CO2) media were added to the cells 2 hr
prior to video imagining on Pulse. To ensure that the
compoundof interestwashomogeneouslymixed in theme-
dia and to keep the amount of liquid added during each
experiment constant, the compound under study was
added at a 23 dilution in freshly prepared pre-equilibratedStemmedium and added with a 50% media change on a 37C
plate in a laminar flow hood. This procedure was carried
out for all concentrations. To correct for vehicle-dependent
effects, control samples underwent media change with the
addition of DMSO reflecting the maximumDMSO concen-
tration in test wells. After compound addition, cells were re-
turned to thePulse systemandallowed to equilibrate 30min
prior to imaging to avoid artifacts caused bymedia addition
and temperature change. After the initial sweep, 15 s videos
were acquired hourly as described in the Experimental Pro-
cedures. A washout step was performed after the experi-
ment; cells were allowed to return to baseline and run on
Pulse again after a minimum of 2 hr. Note that Pulse is de-
signed to image the same areas within a plate for each given
plate format, so even thoughplateswere removed formedia
change after baseline measurement, subsequent measure-
ments were taken from the exact same area of the plate.
In each imaging experiment, videomicroscopy data were
collected from four non-overlapping and pre-defined re-
gions in each well of a 24-well plate (resulting in 96 videos
per experiment). Each video was subsequently analyzed as
described in the Experimental Procedures, generating the
measurements of beating frequency, beat-to-beat variation,
beat duration, amplitude, and prevalence of beating cells.
Videos with beating prevalence of less than 5% were




Figure 4. Ca2+ Imaging Experiments on GCaMP Cells
(A) Response of the beating signal extracted by Pulse to different doses of blebbistatin. The amplitude of the biomechanical beating signal
decreases as the dose increases.
(B) Comparison of the relative amplitude of the biomechanical beating signal before blebbistatin is applied, after 30 min of applying this
compound, and after a media change to wash out blebbistatin. Each drug concentration mean value is based on technical replicates of four
wells with four recordings per well.
(C) No change is seen in the Ca+2 signal.
(D) Beating signal extracted by Pulse and Ca2+ imaging with and without quinidine. Both methods capture an increase in the duration of
the beats. See also Figure S1 for description of genomic modification of the GCaMP cell line used in these experiments.using Fridericia’s formula (Fridericia, 1920). Figure 5 shows
representative examples of beating profiles measured by
Pulse and variation induced by drugs. The bar charts on
the right show the normalized drug response (e.g., dura-
tion) with respect to their baseline, represented by mean
and SEM values. The plots in Figure 5 demonstrate that
our platform successfully captures and quantifies dose-
dependent responses to drugs.
Detection of Changes in Beat Rate
To determine whether Pulse can reliably detect increased or
decreased beat rate, we initially tested the effects of two
compounds: norepinephrine, a beta adrenergic receptor
agonist, and verapamil, which has been shown to act as a
negative chronotrope. We observed a dose-dependent in-
crease in beat rate with the addition of norepinephrine
(see Figure 5A), while verapamil decreased beat rate at
50 nM (see Figure S2A). Cisapride and E-4031 also
decreased the beat rate (see Figures S2B and S2C).
Pulse Detects Prolonged Beat Duration and
Arrhythmias upon Inhibiting hERG
The hERG potassium channel is involved in regulating car-
diac repolarization. In addition to arrhythmia, drugs that626 Stem Cell Reports j Vol. 4 j 621–631 j April 14, 2015 j ª2015 The Authoblock its function have been associated with long QT syn-
drome. On an electrophysiological level, this is reflected
by increased action potential duration. We reasoned that
this should correlate with a change in the duration of phys-
ical contraction as measured by Pulse. We tested the effect
of various concentrations of hERG inhibitors including cis-
apride, E-4031, and sotalol and observed an increase in beat
duration, as shown in Figures 5B, 5C, and 5F, respectively.
This effect was dose dependent, with the exception of
cisapride at 200 nM, the respective maximal dose that
was used. This may be partially due to cytotoxicity, as
we observed beating cessation in several of the 200 nM
cisapride-treated samples. Arrhythmias were observed at
elevated doses for E-4031 and cisapride, as shown in the
traces in Figures 5C and 5B. Notably, this phenomenon
was visible in many, but not all, of the samples treated
within effected doses, suggesting that the arrhythmia
caused by these drugs may be intermittent. We also note
that some of the arrhythmias included shorter ‘‘twitch’’-
like beats, whichmayhave impacted the durationmeasure-
ments. Additional examples are shown in Figure 6,
including 96 beating signals estimated by Pulse and suc-









Figure 5. Drug Testing Experiments
We studied and quantified effect of eight drugs by motion analysis of GCaMP cardiomyocytes. The left panel shows the signals estimated
from a video of one example region before and after the addition of the drug. The bar charts on the right show the variation of a beating
parameter (mean and SEM) for control and different doses at four time points. Each drug concentration included technical replicates of six
wells and four recordings per well, for 24 total measurements. The mean values were calculated by first taking the average of within-well
replicates, reducing the 24 measurements per concentration from 24 to 6, and then calculating the mean and SEM with n = 6.
(A) Norepinephrine. Our method detects a dose-dependent increase in beat rate and decrease in beat duration.
(B) Cisapride. We detect arrhythmic beating patterns, an increase in beat duration, and decrease in beat rate.
(C) E-4031. We detect an arrhythmic beating patterns, an increase in beat duration, and decrease in beat rate.
(D) Verapamil. Our method detects significant decrease in beat duration, as well as decrease in beat rate at high concentrations.
(E) Quinidine. Our method detects a dose-dependent increase in beat duration and decrease in beat rate.
(F) Sotalol. Our method detects a dose-dependent increase in the beat duration.
(G) Nifedipine. Our method detects a dose-dependent increase in the beat duration.
(H) Aspirin. We detect no significant change in beat rate, irregularity, or duration.
See also Figure S2.
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Table 1. Screening the Effect of Drugs on iPSC-Derived Cardiomyocytes
Drug Name Mode of Action Expected Effect Pulse Readout
Norepinephrine B-AR agonist increased beat rate (Peng et al., 2010,
at 0.1 mM)
increased beat rate (0.1, 1, and 20 mM)
Cisapride hERG inhibitor arrhythmia, duration prolongation (Liang
et al. [2013] at 30 nM; Harris et al. [2013]
at 3 nM, statistically significant at 100 nM)
arrhythmia, duration prolongation
(50, 100, and 200 nM)
Quinidine Na+/L-type Ca2+ channel
blocker, hERG inhibitor
duration prolongation (Peng et al. [2010]
at 0.1 mM; Harris et al. [2013] at 0.3 mM)
duration prolongation (0.2, 1, and 3 mM)
Verapamil L-type Ca2+ channel blocker,
hERG inhibitor
Duration shortening (Harris et al., 2013,
at 30 nM)
duration shortening (10, 30, and 50 nM)
E-4031 hERG inhibitor arrhythmia, duration prolongation (Peng
et al. [2010] at 3 nM; Harris et al. [2013]
at 3 nM)
arrhythmia, duration prolongation
(3 and 10 nM)
Sotalol B-AR/hERG inhibitor duration prolongation (Peng et al. [2010]
at 3 mM)
duration prolongation (10 and 30 mM)
Nifedipine L-type Ca2+ channel blocker duration shortening (Peng et al. [2010]
at 30 nM; Harris et al. [2013] at 30 nM)
duration shortening (10 and 50 nM)
Aspirin NSAID none none
Expected effects are from published literature. See also Table S1.Multi-effect Compounds
Having shown that Pulse is able to detect increases in beat
duration associated with hERG channel inhibition, we per-
formed additional verification experiments with inhibitors
of other ion channels, including quinidine, verapamil, and
nifedipine. Quinidine is a class I antiarrhythmic. Primarily
a sodium channel blocker, it also affects calcium and potas-
sium current. As expected, addition of quinidine increased
beat duration at all concentrations tested (Figure 5E). In
contrast, verapamil and nifedipine, L-type calcium chan-
nel blockers, both caused a robust dose-dependent decrease
in the beat duration (Figures 5D and 5G). We also observed
a decrease in the peak height (motion amplitude) with a
nifedipine dose of 50 nM, although not statistically signif-
icant, while at the 500 nM the motion signal is completely
inhibited (Figure S2D). Additionally, aspirin, a non-steroi-
dal anti-inflammatory drug (NSAID), which should have
no effect on cardiomyocyte activity, was run as a negative
control and shown not to alter any of the parameters
measured by Pulse (Figure 5H). Table 1 summarizes the re-
sults of drug screening studies performed in this study,
which show similar trends to the expected effects from
published literature. Table S1 reports values for the motion
signal measured by Pulse and APD90 values reported in
Peng et al. (2010) for a subset of data with comparable
drug concentrations. While differences in cell lines and
protocols prevent a direct comparison, Table S1 confirms
that similar trends are seen between motion data and ac-
tion potential data.628 Stem Cell Reports j Vol. 4 j 621–631 j April 14, 2015 j ª2015 The AuthoDISCUSSION
In this paper, we presented Pulse as an integrated videomi-
croscopy and image-analysis software platform that enables
impartial and unbiased biomechanical motion analysis of
cardiomyocytes in a high-throughput manner. The plat-
form enables users to use standard tissue culture format ves-
sels to analyze the contractile properties of in-vitro-derived
human cardiomyocytes without detailed knowledge of
electrophysiology. Moreover, Pulse is robust enough that
it is capable of analyzing single cells seeded at low density,
in a monolayer or in 3D culture format without additional
input or parameter modification from the user. Pulse is
also completely automated, making it easy to use and
amenable to high-throughput studies, without the need
for extensive post acquisition data processing.
While methods such as manual patch clamp provide
detailed information of the electrical activity of cardiomyo-
cytes, these methods are time consuming and require the
expertise of a trained electrophysiologist. In addition, these
methods are invasive, and generally a single recording can
be performed on the cells at a single time point, hencemak-
ing it difficult to perform longitudinal and long-term
studies on the same set of cells.
Using Pulse, we have demonstrated recapitulation of
well-characterized drug effects in iPSC-derived cardiomyo-
cytes. This platform can be used for high-throughput
cardiotoxicity drug screens and studying physiologically
relevant disease phenotypes such as arrhythmias observedrs
Figure 6. Extracted Beating Signals by Pulse
The plots demonstrate successful detection of arrhythmic beats due to addition of (A) cisapride (50 nm) and (B) E-4031 (10 nm) to the iPS-
CMs from Cellular Dynamics. (A) and (B) are two independent experiments. In each experiment, signals from a single row of a 24-well plate
are shown for four samples per well (total of 24) before and after the addition of drug. Signals are recorded over the duration of 15 s with 24
images per second.in long QT syndrome (Spencer et al., 2014), and abnormal
calcium handling and contractile properties in hypertro-
phic and dilated cardiomyopathy disease models (Lan
et al., 2013; Sun et al., 2012). In addition, the high-
throughput capabilities of Pulse enable the detection of
subtle cellular phenotypes that may otherwise be unde-
tectable due to cell-to-cell variability of the differentiated
iPS-CM.
One current limitation of the Pulse system is the time lag
between one video capture to the next. For example, using
a 96-well format, there is 25-min time lag from the first
video acquisition to the 96th well seconds of recording at
15-s video recordings. This serial scanning time lag limits
the use of Pulse for high-throughput analysis of fast drug
responses. To address this issue, a lower throughput vessel
format (e.g., 6-well plate) can be used. Future development
of the Pulse platform will include a microfluidic drug deliv-
ery system to enable high-throughput analysis of fast drug
responses.
Additional future development of the platform will
include the addition of a fluorescence imaging module toStemallow simultaneous and multi-modal analysis of cardio-
myocytes in a single platform, as well as a mechanism to
pace the cells electrically.EXPERIMENTAL PROCEDURES
Video Microscopy
The Pulse imaging system includes a digital inverted phase-
contrast microscope with a 103 phase objective lens, 625-nm
LED for illumination, and high-speed CMOS camera for image
capturing. The microscope platform is integrated with a high-pre-
cision motorized xy stage, which enables scanning of standard
multi-well plates (6- to 96-well), and a high-quality stage-top incu-
bator that keeps the temperature and CO2 levels uniform. Images
are captured by the camera at a rate of 24 frames/s at 640 3 480
resolution, which is adequate for sampling the beating pattern of
iPS-CMs. Prior to acquisition of each run, the system resets the
stage and then moves the stage automatically and sequentially to
image one or more locations per well, performs auto-focus to
find the optimal focal plane, and subsequently captures a high-
frame-rate image sequence for the duration specified by the user
(typically 10–20 s).Cell Reports j Vol. 4 j 621–631 j April 14, 2015 j ª2015 The Authors 629
iPSC-Derived Cardiomyocytes
To evaluate the performance of Pulse in various cell-culture
conditions and experimental settings, we performed series of
experiments using human iPSC-derived cardiomyocytes from
three independent sources including two commercially available
cells (Axiogenesis and Cellular Dynamics) as well as a genetically
engineered calcium indicator line (GCaMP). Cryo-preserved cardi-
omyocytes were thawed and plated in different multi-well plate
formats (6- to 96-well) and seeded at various densities to obtain sin-
gle cells, small cell clusters, and monolayers.
Axiogenesis and Cellular Dynamics iPS-CMs
Cryo-preserved cardiomyocytes were thawed, plated, and main-
tained according to manufacturer’s instructions on matrigel with
manufacturer supplied (proprietary) media. Cells were plated at
different densities: axiogenesis cardiomyocytes were plated at
10,000–20,000/well in 96-well format and at 43,000–125,000 in
24-well format. Cellular Dynamics cardiomyocytes were plated at
densities between 50,000 and 150,000/well in 24-well format.
Cells were allowed to recover for a minimumof 10 days after thaw-
ing before experimental use. This was dependent on the time it
took for beating parameters to stabilize and reach cell-line-specific
expected values.
GCaMP6f iPSC-Derived Cardiomyocytes
To enable high-throughput and non-invasive monitoring of Ca2+
transients of cardiomyoyctes, the GCaMP iPSCswere generated us-
ing transcription activator like effector nuclease (TALEN)-mediated
targeting of the GCaMP6f (Chen et al., 2013) open reading frame
into the AAVS1 safe harbor locus (Hockemeyer et al., 2011). The
GCaMP6f ORF is driven off a strong constitutive promoter
(CAG), which remains transcriptionally active in the AAVS1 locus
in different cell types and iPS-derived cardiomyocytes, enabling
monitoring of high signal-to-noise ratio.
The GCaMP iPSC lines were differentiated into iPS-CM using
the Wnt modulation differentiation method (Lian et al., 2012).
In brief, iPSCs were treated with 12 mM CHIR99021 (CHIR) in
RPMI/B27 without insulin for 24 hr on day 0, and 5 mM IWP2/
RPMI/B27 without insulin was added on day 3. On day 7, the me-
dia was switched to RPMI/B27 with insulin. On day 15, the cells
were dissociated into single cells using EDTA and cryo-preserved
in FBS+10% DMSO. For experiments, induced cardiomyocytes
were plated at various densities (5,000–42,000/well in 96-well
format and 50,000–110,000/well in 24-well format) on matrigel
in RPMI/B27 with insulin.SUPPLEMENTAL INFORMATION
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